Literature DB >> 31255630

Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.

Chiara Zusi1, Alessandro Mantovani2, Francesca Olivieri3, Anita Morandi3, Massimiliano Corradi3, Emanuele Miraglia Del Giudice4, Marco Dauriz2, Luca Valenti5, Christopher D Byrne6, Giovanni Targher2, Claudio Maffeis7.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the commonest liver disease in children and adolescents in Western countries. Complex traits arise from the interplay between environmental and genetic factors in the pathogenesis of NAFLD. AIMS: We examined the association between NAFLD and eleven single nucleotide polymorphisms (SNPs) at genetic loci potentially associated with liver damage (GCKR, MBOAT7, GPR120), oxidative stress (SOD2), lipid metabolism (PNPLA3, TM6SF2, LPIN1, ELOVL2, FADS2, MTTP) and fibrogenesis (KLF6) in a paediatric population. A genetic risk score (GRS) was performed taking into account both these SNPs and clinical risk factors.
METHODS: We recruited a cohort of 514 obese children and adolescents (mean age [±SD]: 11.2 ± 2.8 years, z-BMI 3.3 ± 0.8). NAFLD was identified by ultrasonography. Genotyping was performed by TaqMan-based RT-PCR system.
RESULTS: The overall prevalence of NAFLD was 67.5% (347 patients). Among the eleven genotyped SNPs, the genetic variants in TM6SF2 rs58542926 (OR = 4.13, p = 0.002), GCKR rs1260326 (OR = 1.53, p = 0.003), PNPLA3 rs738409 (OR = 1.58, p = 0.004) and ELOVL2 rs2236212 (OR = 1.34, p = 0.047) were significantly associated with a higher risk of NAFLD. Addition of a 11-polymorphism GRS to established clinical risk factors significantly (albeit modestly) improved the discriminatory capability of the regression model for predicting the risk of NAFLD (with SNPs C-statistic 0.81 [95%CI 0.75-0.88] vs. 0.77 [0.70-0.84] without SNPs; p = 0.047).
CONCLUSIONS: NAFLD was strongly associated with three genetic variants, TM6SF2 rs58542926, PNPLA3 rs738409 and GCKR rs1260326, and more slightly with ELOVL2 rs2236212, in obese children and adolescents. Addition of a 11-polymorphism GRS to clinical risk factors improved the predictability of NAFLD.
Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Genetics; NAFLD; Nonalcoholic fatty liver disease; Obesity; Pediatrics

Mesh:

Substances:

Year:  2019        PMID: 31255630     DOI: 10.1016/j.dld.2019.05.029

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  11 in total

1.  Factors early in life associated with hepatic steatosis.

Authors:  Sabrina Xin Zi Quek; Eunice Xiang-Xuan Tan; Yi Ping Ren; Mark Muthiah; Evelyn Xiu Ling Loo; Elizabeth Huiwen Tham; Kewin Tien Ho Siah
Journal:  World J Hepatol       Date:  2022-06-27

Review 2.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

Review 3.  Liver Steatosis: A Marker of Metabolic Risk in Children.

Authors:  Costanza Renata Neri; Serena Scapaticci; Francesco Chiarelli; Cosimo Giannini
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 4.  New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History.

Authors:  Jae Sung Ko
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2019-11-11

5.  rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression.

Authors:  Gang Pan; Marco Cavalli; Björn Carlsson; Stanko Skrtic; Chanchal Kumar; Claes Wadelius
Journal:  iScience       Date:  2020-01-09

Review 6.  Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.

Authors:  Serena Scapaticci; Ebe D'Adamo; Angelika Mohn; Francesco Chiarelli; Cosimo Giannini
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-06       Impact factor: 5.555

7.  Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study.

Authors:  Ru Zhang; Minxian Wang; Min Wang; Liuxin Zhang; Yajie Ding; Zongzhe Tang; Zuqiang Fu; Haozhi Fan; Wei Zhang; Jie Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-06       Impact factor: 5.555

Review 8.  Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review

Authors:  Fajar Dwi Astarini; Neneng Ratnasari; Widya Wasityastuti
Journal:  Iran Biomed J       Date:  2022-07-01

Review 9.  Genetic and epigenetic factors determining NAFLD risk.

Authors:  Wenke Jonas; Annette Schürmann
Journal:  Mol Metab       Date:  2020-11-05       Impact factor: 7.422

10.  The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.

Authors:  Jingwen Zhou; Yidi Chen; Jun Yu; Tianci Li; Ziyu Lu; Yan Chen; Xiaolong Zhang; Fang Ye
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.